Table 2

Drug history at censor date of matched cases with JIA-U and control patients with JIA

JIA-U (n=46)JIA (n=46)P value
NSAIDs, n (%)44 (95.7)45 (97.8)1
Intraarticular corticosteroids, n (%)30 (65.2)32 (69.6)0.82
Systemic corticosteroids, n (%)2 (4.3)5 (10.9)0.43
MTX, n (%)23 (50.0)30 (65.2)0.21
Days from JIA diagnosis to first MTX start, median (IQR)31 (13–75)
n=23
46 (21–220)
n=30
0.11
MTX exposure years, median (IQR)0.1 (0.0–1.5)0.5 (0.0–1.5)0.36
Frequency of MTX discontinuation, n (%)0.03*
 No discontinuation7 (30.4)18 (60.0)
 One time13 (56.5)12 (40.0)
 Two times3 (13.0)0 (0.0)
Other cs-DMARDs, n (%)4 (8.7)1 (2.2)0.36
  • *P value <0.05.

  • cs-DMARDs, conventional synthetic disease-modifying antirheumatic drugs; JIA, juvenile idiopathic arthritis; JIA-U, JIA-associated uveitis; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs.